MetaCap

Solesence Inc. (SLSN)

NASDAQ: SLSNConsumer DiscretionaryPackage Goods/CosmeticsUSD

1.41-0.07 (-4.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SLSN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$99.61M
52-week range
0.61 – 2.30
Day range
1.39 – 1.53
Volume / Avg
146.03K / 392.50K
Beta
—

52-week range

$0.61$2.30

SLSN stock today

On Nov 20, SLSN ended the session at $1.41, shedding $0.07 (4.73%), versus the S&P 500's 3.70% decline. Trading was light, with 146.03K shares changing hands, about 37% of the average daily volume. At this level, SLSN sits in the middle of its 52-week range of $0.61 to $2.30: 38.7% below the high, set on Nov 25, 2025 and 131.1% above the low.

SLSN is down 11.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.2%. At 47.0x trailing earnings, Solesence trades above the peer-group median of 10.8x.

Summary generated from market data by MetaCap's automated system. Methodology

About Solesence

Company profile

Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and titanium dioxide ingredients. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients; and skin health products, such as sunscreens and daily care products.

Industry
Package Goods/Cosmetics
CEO
Mr. Kevin Cureton
Headquarters
Romeoville, IL
Employees
115

Financial highlights

Full financials

In fiscal 2025, Solesence generated $62.1 million in revenue, up 18.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $2.8 million (+155.6% year over year), for a net margin of 4.5% versus a median of 2.1% in the prior 5 years. Gross margin was 27.5% (up from 24.9%) and operating margin 4.2%.

Solesence annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$62.06M$52.35M$37.30M$37.32M$29.48M
Growth+18.56%+40.35%-0.05%+26.61%+72.14%
Net income$2.81M$1.10M$-4.94M$-2.62M$2.32M
EPS (diluted)$0.04$0.02$-0.10$-0.05$0.05

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.02 vs —

SLSN news

All SLSN news

Solesence peers

Consumer Discretionary sector
SLSN peer companies
CompanyPrice% ChgMarket capCompare
YSGYatsen Holding Limited ADR1.58-17.28%$148.20Mvs SLSN
WNWMeiwu Technology Company Limited1.65-13.42%$43.31Mvs SLSN
UGUnited-Guardian Inc.7.35+4.11%$33.77Mvs SLSN
AXILAXIL Brands Inc.4.27-5.22%$29.13Mvs SLSN
BYAHPark Ha Biological Technology Co. Ltd. Class A0.8501-18.26%$16.59Mvs SLSN
CABRCaring Brands Inc.0.660.00%$7.59Mvs SLSN
YCBDcbdMD Inc.0.36-5.11%$4.84Mvs SLSN
BIOTInstinct Bio Technical Company Holdings Inc.0.1432-12.15%$4.12Mvs SLSN

Indexes, lists and sector

Solesence stock FAQ

What is Solesence's stock price today?

SLSN last traded at $1.41 as of Nov 20, 4:00 PM EST, down 4.73% on the day. Prices are delayed at least 15 minutes.

What is SLSN's P/E ratio?

SLSN trades at a trailing P/E ratio of 47.00, compared with a median of 10.8 for its closest peers.

Who is Solesence's CEO?

Mr. Kevin Cureton is the chief executive officer of Solesence Inc., which has about 115 employees.

What is the SLSN 52-week high?

The 52-week high for SLSN is $2.30 and the 52-week low is $0.61. The stock is currently 38.7% below its high.

Compare SLSN